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Was America sleeping on its laurels or just snubbing
molecular allergology / component-resolved diagnosis?
The clinical implementation of molecular allergology
testing in Europe dates back to the early 2000’s. Although
the importance of major allergens seems to have been
readily recognized by allergy professionals in North
America, more exhaustive exploration and clinical use of
molecular allergology is still waiting. In this day and age
of instant communication and worldwide professional
collaboration, it is surprising that such a gap could have
developed. A review of factors that may have led to this
situation represents an opportunity to identify important
dynamics that sometimes hinders the introduction of
valuable science and/or technologies to our patient care.
In France, the model of physician remuneration may
have set up the opportunity for the professional coopera-
tion that developed the science and its integration to
government-sponsored healthcare services. In Canada,
the lack of expertise and demand for molecular allergol-
ogy services has hindered the country-specific certifica-
tion process of laboratory technology otherwise widely
recognized. In the US, the FDA is still restricting its
endorsement to the “Peanut-You-Know” portion of
Thermofisher’s line of molecular allergy testing products.
All the while and until recently, pioneering US-based
research in oral immunotherapy (OIT) neglected basic
data concerning peanut allergy molecular profiles at a
time when comprehensive protocols were routine clinical
practice in some French centers. Whereas www.allerdata.
com and www.allergome.com websites provide a bounty
of information about molecular allergology, language
issues (French/English, basic science/clinical) may have
impeded the dissemination of the science. Realities remote
from the objective value of molecular allergology / compo-
nent-resolved diagnosis may explain the gap in clinical
implementation between Europe and North America. If
the latter is to assert a dominant role in the field of allergy,
its professionals will have to embrace change and provide
leadership in molecular allergology. As for sublingual
immunotherapy, inaction on the part of allergy profes-
sionals will leave to commercial and industrial interests
the definition of the business model and ultimately the
patients’ health care options.
Published: 17 March 2014
doi:10.1186/2045-7022-4-S2-P34
Cite this article as: Tropper: Molecular allergology in North America;
understanding the delay. Clinical and Translational Allergy 2014 4(Suppl 2):
P34.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submitAVANT GARDE Médical, 550 Boul. De Mortagne, Suite 260, Boucherville, J4B
5E4, Canada
Tropper Clinical and Translational Allergy 2014, 4(Suppl 2):P34
http://www.ctajournal.com/content/4/S2/P34
© 2014 Tropper; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://
creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
